World 1st Medical Grade
Bioactive Filament for
3D Printing

Clients & Collaborators

Printing Bone 
Implant with 
Bioactivity
Bone implants have been made with various methods and materials. Polymer being one of the most interesting materials is a versatile platform with tremendous potential in bioactivity and mechanical performance. In Ossfila, we created Bonlecule, the building block in making bioactive implants readily.

Print to order services

Print to order services

From getting the CT images of the bone to model the missing piece of bone and get it 3D printed with bioactive materials take only less than a week here in Ossfila. The printed bone can also be sterilized by EtO and packaged based on medical device industry standard.

Rocket Nanomaterial Science

Rocket Nanomaterial Science

Making a 3D printed implant is not a rocket science. However, making a bioactive filament which can be made into implants and integrate with your body requires intense R&D. Bonlecule is the only commercially available hydroxyapatite enhanced bioactive FDM filament.

Available Online

Available Online

Bonlecule bioactive filament for 3D printing can be ordered online with just a few clicks. For tailored 3D printed implant, please contact our sales representatives

The Technology

OSSFILA is a Hong Kong Science Technology Park (HKSTP) member company deploying bioactive 3D printed materials and implants with our novel bioactive material. Our Team is comprised of scientists and engineers recruited globally to bring technological breakthrough to our products. OSSFILA’s flagship biomaterial – Bonlecule is created to positively reshape the quality of life and minimise the repercussions post bone implant surgery.

Governmental and Institutional Bondings

OSSFILA is supported by Hong Kong SAR Government R&D research grants. We recognises R&D as the main driver to improve our products. We continuously strengthen collaborations with industries and universities for a sustainable research and commercialization model. In OSSFILA, we work closely with regulators, medical affairs, scientists and clinicians.